CEDRA Corporation, a division of Worldwide Clinical Trials, announced that it has purchased the Gyrolab™ xP workstation for use in its bioanalytical research, specifically for ligand binding analysis. CEDRA is employing the new Gyrolab in its Ligand Binding Assay (LBA) laboratory in Austin, Texas, and is the only CRO in North America to offer this technology to the pharmaceutical industry.

The Gyrolab represents significant innovation in the automation and advancement of
bioanalytical research. The patented technology transforms the numerous steps involved in
conventional LBA applications and streamlines them into single, nanoliter-scale procedures.
Efficiency and productivity are significantly boosted with the Gyrolab's ability to miniaturize and
integrate assay steps for protein quantification immunoassays.

"We believe the addition of the Gyrolab to our LBA laboratories is significant and represents
our dedication to enhancing the capabilities offered to the biopharmaceutical research industry," said William Nowatzke, Ph.D., Director, Ligand Binding Assay Group, CEDRA Corporation. "A key driver to our business is the dedication to staying on the forefront of technology. The addition of the Gyrolab complements our other four LBA platforms, permitting CEDRA to transfer or develop practically any LBA method. One of the key strengths of the Gyrolab is its miniaturized assay format requiring extremely small sample volumes -- nanoliters -- ultimately minimizing the consumption of precious sample volume," continued Dr. Nowatzke. "It eliminates cumbersome multiplexing practices."

Source: web of pharmoutsourcing